EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Plasma exchange with albumin replacement for Alzheimer's disease treatment induced changes in serum and cerebrospinal fluid inflammatory mediator levels

Ricardo Gonzalo, Carla Minguet, Ana María Ortiz, María Isabel Bravo, Oscar L López iD, Mercè Boada, Agustín Ruiz, Montserrat Costa iD

Annals of Clinical and Translational Neurology · 2024

DOI: 10.1002/acn3.52235 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Ricardo Gonzalo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Grifols Scientific Innovation Office, Avinguda de la Generalitat 152-158, Sant Cugat del Vallès, 08174, Barcelona, Spain. Hauptthemen laut MEDLINE: Alzheimer Disease, Plasma Exchange. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grifols.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

There is extensive literature indicating that inflammatory pathways are affected in Alzheimer's disease (AD). We examined whether plasma exchange with albumin replacement (PE‐Alb) can impact the inflammatory status of AD patients and alter the relationship between inflammatory mediators and cognitive measures.

Methods

Serum and cerebrospinal fluid (CSF) samples from 142 AD patients participating in the AMBAR trial (14‐month schedule of PE‐Alb treatment vs. placebo [sham PE‐Alb]) were analyzed for changes from baseline for 19 inflammatory mediators (6 inflammatory cytokines, 9 chemokines, and 4 vascular injury indicators) at representative time points across the AMBAR study (lasting effects) as well as in pre‐ versus post‐PE‐Alb procedure (acute effects). Association between mediator changes and clinical outcomes reported in the AMBAR study (cognitive, functional, behavioral function, and global change tests) was assessed.

Results

PE‐Alb significantly reduced IFN‐γ, eotaxin, MIP‐1α and ICAM‐1 levels in serum, and eotaxin‐3 and MIP‐1β levels in CSF, at various time points during treatment ( p < 0.05; false discovery rate‐corrected). Vascular injury indicators were the mediators mostly affected by post‐ versus pre‐PE‐Alb level reduction. Increased serum MIP‐1α levels were associated with worsening in ADAS‐Cog, CDR‐sb, and ADCS‐CGIC scores in the placebo group, but not in the PE‐Alb‐treated group.

Interpretation

Peripheral intervention could affect AD by reducing inflammatory mediators in both peripheral and central compartments. Changes in MIP‐1α due to PE‐Alb were associated with changes in clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseasePlasma ExchangeHumansMaleFemaleAgedInflammation MediatorsMiddle AgedAlbuminsAged, 80 and overCytokines

Substanzen

Inflammation MediatorsAlbuminsCytokines

Autor:innen und Institutionen

  • Grifols Scientific Innovation Office, Avinguda de la Generalitat 152-158, Sant Cugat del Vallès, 08174, Barcelona, Spain.
  • Departments of Neurology and Psychiatry, University of Pittsburgh School of Medicine, 811 Kaufmann Medical Building, 3471 Fifth Avenue, Pittsburgh, 15213, Pennsylvania, USA.
  • ACE Alzheimer Centre Barcelona - Universitat Internacional de Catalunya, Gran Via de Carles III, 85 BIS, Barcelona, 08028, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Calle de Melchor Fernández Almagro 3, Fuencarral-El Pardo, Madrid, 28029, Spain.

ORCID-Profile: Oscar L López, Montserrat Costa

Förderung

  • Grifols

Zitieren

APA

Gonzalo, R., Minguet, C., Ortiz, A. M., Bravo, M. I., López, O. L., Boada, M., Ruiz, A., & Costa, M. (2024). Plasma exchange with albumin replacement for Alzheimer's disease treatment induced changes in serum and cerebrospinal fluid inflammatory mediator levels. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52235

Vancouver

Gonzalo R, Minguet C, Ortiz AM, Bravo MI, López OL, Boada M, et al. Plasma exchange with albumin replacement for Alzheimer's disease treatment induced changes in serum and cerebrospinal fluid inflammatory mediator levels. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52235

BibTeX
@article{Gonzalo2024,
  author = {Gonzalo, Ricardo and Minguet, Carla and Ortiz, Ana María and Bravo, María Isabel and López, Oscar L and Boada, Mercè and Ruiz, Agustín and Costa, Montserrat},
  title = {Plasma exchange with albumin replacement for Alzheimer's disease treatment induced changes in serum and cerebrospinal fluid inflammatory mediator levels},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  doi = {10.1002/acn3.52235}
}
Kostenlos starten →